Scientists are rapidly examining retatrutide, a novel drug from Eli Lilly, as a potential step in physique reduction . Distinct from many previous approaches, retatrutide is a dual -action agonist targeting both GLP-1 and GIP, hormones that influence appetite and blood sugar control . Initial re… Read More